Effect of Imipramine on radiosensitivity of Prostate Cancer: An In Vitro Study

Cancer Invest. 2019;37(9):489-500. doi: 10.1080/07357907.2019.1662434. Epub 2019 Sep 9.

Abstract

Prostate cancer is the most common cancer and leading cause of cancer death for males. Imipramine (IMI), which is a tricyclic antidepressant, has also been shown to has antineoplastic effect. This study was performed to investigate the radiosensitizing effect of IMI on DU145 prostate cancer cell. Cells were divided into 4 groups. Cell index, apoptotic activity, cell cycle arrest, oxidative stress and EAG1 channel currents were determined in all groups. Our findings showed that combined treatment with IMI and radiotherapy (RAD) did not enhance radiosensitivity of DU145 cells but as unexpected finding, treatment of IMI alone was more effective in DU145 cells.

Keywords: EAG1 channel; Imipramine; cell index; oxidative stress; prostate cancer; radiotherapy.

MeSH terms

  • Cell Cycle / drug effects
  • Cell Cycle / radiation effects
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Down-Regulation
  • Ether-A-Go-Go Potassium Channels / metabolism*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Imipramine / pharmacology*
  • Male
  • Oxidative Stress / drug effects
  • Oxidative Stress / radiation effects
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / therapy
  • Radiation-Sensitizing Agents / pharmacology*
  • Radiotherapy

Substances

  • Ether-A-Go-Go Potassium Channels
  • KCNH1 protein, human
  • Radiation-Sensitizing Agents
  • Imipramine